The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer

Francesca Battaglin, Alberto Puccini, Selma Ahcene Djaballah, Heinz-Josef Lenz

Research output: Contribution to journalArticle


Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is currently approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) in combination with chemotherapy in first- and second-line and as monotherapy in chemorefractory patients. This review will provide an overview of main efficacy data on panitumumab from its early development up to latest evidences, including novel perspectives on predictive biomarkers of anti-EGFRs efficacy and mechanisms of secondary resistance. Quality of life (QoL) related issues and panitumumab safety profile will be addressed as well.

Original languageEnglish
Pages (from-to)5911-5924
Number of pages14
JournalCancer Management and Research
Publication statusPublished - 2019


Cite this